CD4+ T cells are the major predictor of HCMV control in allogeneic stem cell transplant recipients on letermovir prophylaxis.

Front Immunol · 2023 · PMC10206124 · PMID 37234158

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, alloSCT recipients receiving preemptive therapy showed a trend toward higher T-cell counts from day +30 to day +120 than those on letermovir prophylaxis, most markedly at day +120 [median: 235 vs. 58 CD3 + CD56 - T cells/μL, median-to-median ratio (MMR)=4.1, p=0.135, Figure 2B ].

also in 53,322 other papers

a strong trendno p-value reported

Interestingly, we also found a strong trend towards increased frequencies of CD159c + and mature CD57 + CD159c + “memory-like” NK cells in NSTR vs.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.